Business
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)
Term loan maturity extended by 12 months to June 2029Principal balance on term loan expanded to $13.0 million from $11.1 million currentlyExpanded revolving
About this update from Aytu Biopharma, Inc.
[{"type":"text","content":"Term loan maturity extended by 12 months to June 2029Principal balance on term loan expanded to $13.0 million from $11.1 million currentlyExpanded revolving line of credit facility by $1.5 millionExpanded facilities allow for added working capital flexibility as commercial launch of EXXUA is anticipated to occur in the fourth calendar quarter of 2025 DENVER, CO / ACCESS Newswire / June 23, 2025 / Aytu BioPharma, Inc. (the \"Company\" or \"Aytu\") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced it has successfully expanded and extended its lending agreement with Eclipse Business Capital LLC (\"Eclipse\"), providing added working capital flexibility as the Company prepares for the commercial launch of EXXUA™ (gepirone) extended-release tablets (\"EXXUA\"). Gepirone is a new chemical entity, and EXXUA is the first-in-class selective serotonin 5HT1a receptor agonist approved by the United States Food and Drug Administration (\"FDA\") for the treatment of major depressive disorder (\"MDD\") in adults.Earlier this month, Aytu announced an exclusive agreement to commercialize EXXUA in the United States entering the Company into the over $22 billion United States prescription MDD market. Over 340 million antidepressant prescriptions were written in 2024 in the United States, yet significant unmet needs remain considering the unacceptable side effects associated with current therapeutics. EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, the incidence of sexual side effects experienced with EXXUA was comparable to placebo.\"Following the transformational agreement we entered into earlier this month to commercialize EXXUA, which included the closing of a $16.6 million public offering priced at the market and included the full exercise of the overallotment, we have successfully expanded and extended our lending agreement with Eclipse to provide added working capital flexibility as we prepare for the EXXUA launch later this calendar year,\" commented Josh Disbrow, Chief Executive Officer of Aytu. \"With EXXUA expected to serve as a major growth catalyst for us for years to come, it is gratifying to have the support of...